January 20, 2025 06:48 AM EST

Another US biotech emerges with drug candidate from China-based Keymed

Kyle LaHucik

Senior Reporter

The China-to-US experimental medicine pipeline is ballooning: yet another US-based biotech formed around a candidate from China’s Keymed Biosciences on Monday.

Life sciences investment firm …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Another US biotech emerges with drug candidate from China-based Keymed

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Sage sues Biogen days after $469M buyout offer

Sionna and Odyssey end JPM week with IPO filings

FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefit

What Trump's CMS can and can't change with the second round of drug price negotiations

A mixed year for deals and dollars left biotech execs hungry for a better 2025

Fueling More Breakthroughs: Manufacturing Innovation to Expand Gene Therapy’s Reach

An­oth­er US biotech emerges with drug can­di­date from Chi­na-based Keymed

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Another US biotech emerges with drug candidate from China-based Keymed